Clay Siegall – Highly Acclaimed Scientist and Founder of Seattle Genetics

Clay Siegall is a well-known personality in the biotechnology and biopharmaceutical industry and is the founder and chairman of the highly successful biotech firm named Seattle Genetics. The focus of Seattle Genetics is research and developing effective therapies for the disease types that has not seen much development regarding mortality improvements in the last couple of decades. Clay Siegall is a highly qualified scientific researcher and holds Ph.D. from George Washington University and Bachelor of Science in Zoology from the Maryland University.

 

Under the leadership of Clay Siegall, Seattle Genetics has achieved many milestones and has also acquired the FDA approval for the antibody drug conjugate. The approved conjugate is currently available in the market with different approved indications. Clay Siegall has also helped Seattle Genetics collaborate with many pharmaceutical giants like Pfizer, Bayer, Genentech, and more. It has contributed to improving the market positioning of Seattle Genetics and has considerably improved the company’s revenue.

 

Clay Siegall has helped tremendously in making Seattle Genetics one of the biggest players in the biotechnology space, especially in the field of developing effective cancer therapies. The company has many new drugs under development that are waiting for approval before commercial production. All this and more has helped Seattle Genetics, one of the leading pharmaceutical firms that are growing exponentially through its stronghold in research and development. In an interview recently, Clay Siegall mentioned about how he developed an interest in medical science. He said that when one of the family members was diagnosed with Cancer, he saw the relative suffer more due to the treatment than due to the disease itself. And, it is also one of the reasons why he believes that in future chemotherapy would be replaced by targeted therapies.

 

Clay Siegall also highlighted the source of revenue for Seattle Genetics, which includes selling the company proprietary drugs and also by leasing out the technologies and process that are patented by Seattle Genetics. Clay Siegall also said that production partnerships are also one of the income generators for Seattle Genetics. Clay Siegall has helped the firm raise funds of more than a billion dollar since its inception through various fundraising initiatives.